CD28 Market Overview, Growth, Trends, Analysis, Research Report (2025-2031)

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2025-2031

Coverage: CD28 Market covers analysis By Type (FPT-155, FR-104, Lulizumab Pegol, Others); Application (Plaque Psoriasis, Solid Tumor, Acute Renal Failure (ARF), Others); and Geography , and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Date : Nov 2025
  • Report Code : TIPRE00021838
  • Category : Life Sciences
  • Status : Upcoming
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 150
Page Updated: Jul 2025

The CD28 Market is expected to register a CAGR of XX% from 2025 to 2031, with a market size expanding from US$ XX Million in 2024 to US$ XX Million by 2031.

The report is categorized by Type (FPT-155, FR-104, Lulizumab Pegol) and further analyzes the market based on Application (Plaque Psoriasis, Solid Tumor, Acute Renal Failure). A comprehensive breakdown is provided at global, regional, and country levels for each of these key segments.

The report includes market size and forecasts across all segments, presenting values in USD. It also delivers key statistics on the current market status of leading players, along with insights into prevailing market trends and emerging opportunities.

Purpose of the Report

The report CD28 Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  • Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  • Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  • Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

CD28 Market Segmentation

Type

  • FPT-155
  • FR-104
  • Lulizumab Pegol

Application

  • Plaque Psoriasis
  • Solid Tumor
  • Acute Renal Failure

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

CD28 Market: Strategic Insights

cd28-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

CD28 Market Growth Drivers

  • Unlocking New Partnerships for CD28 Innovation
  • Expanding Global Reach in Immunotherapy
  • Enhancing Patient Engagement for Better Outcomes

CD28 Market Future Trends

  • AI-Powered Immunotherapy Revolutionizes CD28 Market Dynamics
  • Personalized Medicine Takes Center Stage in CD28 Therapeutics
  • Sustainable Manufacturing Practices Transform CD28 Production Landscape

CD28 Market Opportunities

  • Unlocking CD28's Potential: Innovative Therapies for Autoimmune Diseases
  • Revolutionizing Cancer Treatment: CD28 as a Target for Immunotherapy
  • Personalized Medicine: Tailoring CD28-Targeted Treatments for Patients

CD28 Market Regional Insights

The regional trends and factors influencing the CD28 Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses CD28 Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

CD28 Market Report Scope

Report Attribute Details
Market size in 2024 US$ XX Million
Market Size by 2031 US$ XX Million
Global CAGR (2025 - 2031) XX%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Type
  • FPT-155
  • FR-104
  • Lulizumab Pegol
By Application
  • Plaque Psoriasis
  • Solid Tumor
  • Acute Renal Failure
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Atox Bio Ltd
  • Bristol-Myers Squibb Co
  • Five Prime Therapeutics Inc
  • Johnson and Johnson
  • TheraMAB LLC
  • Boster Bio
  • Aviva Systems Biology
  • Biobyt
  • Genetex

  • CD28 Market Players Density: Understanding Its Impact on Business Dynamics

    The CD28 Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.


    cd28-market-cagr

    • Get the CD28 Market top key players overview

    Key Selling Points

    • Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the CD28 Market, providing a holistic landscape.
    • Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
    • Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
    • Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

    The research report on the CD28 Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.

    Mrinal Kerhalkar
    Manager,
    Market Research & Consulting

    Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

    Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset

    Testimonials

    Reason to Buy

    • Informed Decision-Making
    • Understanding Market Dynamics
    • Competitive Analysis
    • Identifying Emerging Markets
    • Customer Insights
    • Market Forecasts
    • Risk Mitigation
    • Boosting Operational Efficiency
    • Strategic Planning
    • Investment Justification
    • Tracking Industry Innovations
    • Aligning with Regulatory Trends
    Our Clients
    Sales Assistance
    US: +1-646-491-9876
    UK: +44-20-8125-4005
    Email: sales@theinsightpartners.com
    Chat with us
    DUNS Logo
    87-673-9708
    ISO Certified Logo
    ISO 9001:2015
    ISO Certified Logo